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Hyperthermia used as an adjuvant with chemotherapy is highly promising in the treatment of certain
cancers. Currently, the small molecule drugs used in combination with hyperthermia were not designed
for this application. Herein, we report the evaluation of a chlorambucil and a ruthenium compound
modiﬁed with a long ﬂuorous chain, which exhibit thermoresponsive activity in colorectal
adenocarcinoma xenografts in athymic mice in combination with mild hyperthermia (42 C).
Intraperitoneal injection of the derivatives followed by local hyperthermia showed a synergistic tumor
growth reduction by 79% and 90% for the chlorambucil and ruthenium-based derivatives, respectively,
with the latter exhibiting a higher synergy in combination with hyperthermia compared to the
monotherapies. Histological analysis shows that both derivatives in combination with hyperthermia
signiﬁcantly decrease the number of proliferating tumor cells.Introduction
The most widely applied anticancer drugs tend to exhibit severe
side-eﬀects1 and, consequently, considerable eﬀorts have been
directed towards the design of more selective anticancer drugs
or treatment protocols that reduce side-eﬀects and improve the
quality of life of the patient, both during and aer chemo-
therapy. It has been shown that combining chemotherapy with
regional mild hyperthermia (applying heat locally to raise the
tumor temperature between 40 and 42 C), can sensitize tumor
tissue to anticancer agents resulting in improved local control,
treatment eﬃcacy and overall survival prolongation.2,3 A prom-
ising approach used to enhance drug action when combined
with hyperthermia is to employ drugs that are activated only
under hyperthermia conditions.4,5
Attaching known drugs to thermoresponsive macromole-
cules has led to hyperthermia treatments that are considerably
more eﬀective and selective than the application of the drug
alone.6–11
For example, doxorubicin has been extensively studied in
liposomal formulations designed for thermoresponsive
release,11,12 which also benet from preferential accumulation
in solid tumors due to the enhanced permeability and retention
eﬀect that relies on microvascular hyperpermeability to
macromolecules.13–15 One such formulation termed
ThermoDox® is based on a low temperature sensitive liposomeques, Ecole Polytechnique Fe´de´rale de
itzerland. E-mail: paul.dyson@ep.ch;
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hemistry 2015containing doxorubicin, which upon heating to 42 C releases
the doxorubicin.16,17 ThermoDox® is currently in phase III clin-
ical trials in combination with radiofrequency ablation for the
treatment of hepatocellular carcinoma.18
Hyperthermia used as an adjuvant with chemotherapy, but
also with radiotherapy19,20 or their combination, also shows
promise in cancer treatment. A triple therapy comprising
radiotherapy, hyperthermia and chemotherapy, employing
temozolomide (with liposomal doxorubicin included in resis-
tant cases), led to enhanced survival rates in a glioblastoma
clinical trial.21 In this study over 50% of patients showed pro-
longed survival to 26 months whereas the median survival
following surgery is usually less than 4 months, which slightly
increases with radiotherapy.22,23 Chlorambucil has also been
encapsulated in a biodegradable and thermoresponsive
micellar system based on triblock copolymers that increase
water solubility and control its release near the tumor.24,25
Methods to transform anticancer drugs such as doxorubicin,
chlorambucil, cisplatin and other compounds into thermores-
ponsive agents focus mainly on the use of macromolecules,
notably liposomal formulations, or magnetic nanoparticles that
encapsulate the drug and deliver it at the tumor site under
hyperthermia.26–31Nevertheless, replacing macromolecules with
low molecular weight thermosensitive drugs remains an
attractive alternative option due, in part, to the variability and
complexity of nanoscale medicines.
We have recently shown that peruorinated chains cova-
lently bound to small molecule drugs give rise to thermores-
ponsive solubility, i.e. low solubility that rapidly increases with
small increases in temperature, with the change in solubilityChem. Sci., 2015, 6, 2795–2801 | 2795
Fig. 1 Chemical structures of chlorambucil, RAPTA-C and the thermoactive derivatives 1 and 2.
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View Article Onlinebeing considerably greater than that of the parent drug. A
modied chlorambucil derivative 132 and a monofunctional
RAPTA-C like ruthenium(II) compound 233 (see Fig. 1) are
essentially non-cytotoxic at 37 C and highly cytotoxic to cancer
cells when activated by a 2 hour hyperthermia signal (41.5 C).
In this study, compounds 1 and 2 were evaluated in a pre-clin-
ical model in combination with mild hyperthermia validating
their synergy in cancer treatment in vivo.
Results and discussion
Human adenocarcinoma LS174T cells were implanted subcu-
taneously on the hind leg of athymic mice, as local mild
hyperthermia can easily be applied at this site, and were allowed
to grow until a palpable tumor mass was observed. The
compounds (1 or 2) were injected intraperitoneally (i.p.) at a
dose of 12.5 mg per kg per day in a 10% DMSO solution in
sterile saline (0.9% NaCl) with control groups receiving a 10%
DMSO saline solution. In parallel monotherapy groups with
hyperthermia treatment only (30 minutes at 42 C) or 1 or 2 onlyFig. 2 LS174T adenocarcinoma growth inhibition in athymic mice. Mic
(indicated by the green arrows) with or without mild hyperthermia (42 C
group animals were treated with 10% DMSO in sterile saline (0.9% NaCl) a
error of the mean, SEM (n ¼ 5 to 8 mice/group, ANOVA, **p < 0.01, ***p
using the formula: volume ¼ width2  length  0.5.
2796 | Chem. Sci., 2015, 6, 2795–2801were studied. Dual therapy was performed by injection of the
compound followed by hyperthermia treatment with a drug-
hyperthermia interval of a maximum of 15 minutes. The rapid
induction of hyperthermia following drug injection was shown
to be optimal for several clinically approved drugs, e.g. cisplatin,
melphalan and carboplatin.34–37
Tumor growth was measured daily starting at the rst day of
treatment (day 6, following inoculation on day 0). The median
tumor volume of each group for 1 is shown in Fig. 2.
Signicant tumor inhibition from day 7 to 18 is observed
(based on ANOVA testing). In addition, post ad-hoc statistical
analysis using the one-sided pairwise t-test indicates that 1
alone (p ¼ 0.00184), hyperthermia alone (p ¼ 0.00610) and the
duotherapy of 1 + hyperthermia (p ¼ 3.2  104) signicantly
reduce tumor growth compared to the control group. Indeed, on
the last day of the experiment, duotherapy gives a drug eﬃcacy
of 79% versus 59% (for 1 alone) and 45% (for hyperthermia
alone), with the 1 + hyperthermia duotherapy acting synergis-
tically on tumor growth reduction following the fractional
product, DE1,H ¼ 0.787 (see Experimental). It should be notede were treated with 1 (12.5 mg kg1, 300 mL i.p.) given every 4 days
for 30 minutes) within 15 minutes following drug injection. The control
lso given every 4 days. Results are expressed as medians the standard
< 0.001), eﬃcacy DE1,H ¼ 0.787. Tumor volume (mm3) was calculated
This journal is © The Royal Society of Chemistry 2015
Fig. 3 LS174T adenocarcinoma growth inhibition in athymic mice. Mice were treated with 2 (12.5 mg kg1, 300 mL i.p.) given every 4 days
(indicated by green arrows) with or without mild hyperthermia (42 C for 30 minutes) administered intraperitoneally. The vehicle control was
treated with three doses of 10% DMSO in sterile saline (0.9% NaCl) also given every 4 days. Values plotted are medians the standard error of the
mean, SEM (n ¼ 5–8 mice per group, ANOVA, **p < 0.01, ***p < 0.001), eﬃcacy DE2,H ¼ 0.899.
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View Article Onlinethat hyperthermia alone has previously been shown to reduce
tumor size in patients,38 as cancer cells are more sensitive than
normal cells to mild hyperthermia (41–43 C).39,40
The same in vivo model was also used to evaluate in duo-
therapy 2 with hyperthermia on tumor growth reduction (Fig. 3)
using the protocol described for 1. ANOVA testing conrmed
signicant tumor growth reduction and post ad hoc statistical
analysis using the one-sided pairwise t-test gave signicant
diﬀerences in tumor growth for 2 alone (p ¼ 0.0013), hyper-
thermia alone (30 minutes at 42 C, p ¼ 0.0058) and 2 +
hyperthermia (p ¼ 7.4  105) compared to the control group.
Moreover, the tumor volume in the mice undergoing duother-
apy is signicantly diﬀerent from hyperthermia alone and from
2 given as a monotherapy (*p-values < 0.05). Compound 2
inhibited tumor growth by 66%, whereas the duotherapy of 2 +Fig. 4 Histochemical analysis of tumors stained for proliferating cells (Ki6
are shown. Ki67 + nuclei are indicated with red arrows. Scale bar ¼ 100 m
errors are shown as means  the standard error of the mean (right).
This journal is © The Royal Society of Chemistry 2015hyperthermia resulted in tumor growth inhibition of 90%,
with the combination displaying strong synergistic eﬀects
(DE2,H ¼ 0.899).
In order to detect proliferating cells, treated tumor tissue
sections from the various studies were stained with the nuclear
proliferation marker Ki67 (Fig. 4). Hyperthermia by itself
showed an anticancer eﬀect, decreasing the number of
proliferating cells by 33% (p ¼ 0.0462). The application of 1 or 2
both signicantly reduces the number of proliferating cells
(28%, p ¼ 0.041 and 37%, p ¼ 0.0465, respectively). Duotherapy
of 1 + hyperthermia resulted in a 84% decrease of proliferating
cells (p ¼ 0.0037), whereas 2 + hyperthermia inhibited prolif-
erating tumor cells by 91%, i.e. inducing an enhanced state of
quiescence. This cellular quiescence, or proliferation arrest,
presumably represents a homogeneous state induced by diverse7). Representative sections of tumors of the diﬀerent treatment groups
m (left). Quantiﬁcation of proliferating tumor cells per treatment group,
Chem. Sci., 2015, 6, 2795–2801 | 2797
Fig. 5 Histochemical analysis of tumor necrosis using hematoxylin and eosin (H&E) staining. Representative sections of tumors from diﬀerent
treatment groups are shown. Tumor necrosis is observed in the hyperthermia group and is extensive in the 2 + hyperthermia group (indicated by
the black arrows). Scale bar ¼ 100 mm.
Fig. 6 Ruthenium content in tissues (ng mg1 of wet tissue) after mouse sacriﬁce for 2 applied as a monotherapy and 2 used in duotherapy with
hyperthermia. Values are means  SEM.
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View Article Onlineanti-mitogenic signals.41 Previously, it was shown that RAPTA-C
treated mice bearing LS174T tumors leads to similar eﬀects,42
however, RAPTA-C was administered daily at 100 mg kg1, an 8-
fold higher dose than 2 (12.5 mg kg1 given every 4 days).
Hyperthermia combined with known chemotherapy agents has
previously been shown to lead to some necrosis,43 which was
also observed with 1 and 2 (Fig. 5). However, with these
specially-designed thermoactive compounds, antiproliferative
activity is eﬃciently triggered by a short mild hyperthermia
signal without apparently aﬀecting the surrounding tissues,
therefore providing enhanced selectivity.
Treatment toxicity and side-eﬀects of the monotherapies and
duotherapy were assessed by monitoring the relative body-
weight of the mice on daily basis. At the end of the experiment
the average body weight of the mice was not signicantly
diﬀerent between all the treatment groups. At a behavioral level
no unusual changes were observed including no change in food
and water intake throughout the experiment period. Moreover,
acute induction of inammation of the tumors was not
observed. Since ruthenium is not naturally present in living
organisms, the distribution of ruthenium in tissues was2798 | Chem. Sci., 2015, 6, 2795–2801determined aer sacricing mice treated with either 2 alone or
in duotherapy. Organs were removed and dried, digested in
nitric acid, and their ruthenium content determined by ICP-MS
(Fig. 6).
Ruthenium accumulates in the kidneys, an organ associated
with penetration and elimination of drugs, similar to that
observed for the antimetastatic ruthenium(III) drug NAMI-A,
which accumulates in kidneys in a dose-dependent manner,44
and in RAPTA-C-treated mice.42 Ruthenium also accumulates in
the liver, but two fold less than in kidneys, followed by the
stomach and spleen. The concentration of ruthenium in the
lungs is low, in contrast to NAMI-A, which exhibits equivalent
concentrations in lungs, kidneys and liver.45 Notably, duother-
apy with hyperthermia does not signicantly aﬀect the ruthe-
nium distribution in the organs.Conclusions
We have validated the concept of using small molecule ther-
moresponsive compounds in combination with hyperthermia
to inhibit tumor growth. Two very diﬀerent classes of drugs withThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineperuorinated chains were studied, with the peruorinated
chain endowing the compounds with thermomorphic proper-
ties. Compound 1, which is derived from the alkylating agent
chlorambucil, and 2, which is structurally related to a
compound that selectively targets histone proteins in chro-
matin,46,47 exhibit a synergistic tumor growth reduction in
duotherapy with local hyperthermia, with 2 showing a higher
synergistic level with hyperthermia than 1, and resulting in a
90% reduction of tumor growth. Attempts were not made to
elucidate the biomolecular targets of 1 and 2, however, it is not
unreasonable to assume that 1, like chlorambucil, targets DNA
(since the uorous chain can be lost following cellular uptake),
and that 2 may behave in the same way as other bifunctional
ruthenium(II)-arene compounds.47,50 Notably, duotherapy
decreases the number of proliferating cancer cells and
enhances tumor necrosis in the absence of systemic damage to
the surround tissues and organs. These ndings not only vali-
date the strategy, but also indicate more generally that drug
modication with peruorinated chains may enhance tumor
growth inhibition eﬃcacy without inducing additional side-
eﬀects, and could be applied to other drugs currently used in
the clinic to treat cancer.Experimental
Compounds 1 and 2 were prepared as described previously.32,33
Compounds were dissolved in DMSO (Sigma-Aldrich) and
diluted to a nal concentration of 12.5 mg kg1 in sterile saline
(0.9% NaCl) prior i.p. injections. The control group animals
were treated with 10% DMSO in sterile saline (0.9% NaCl) also
given every 4 days.Cell implantation in athymic mice and treatment protocol
Experiments in 8 week old Swiss female athymic mice
purchased from Charles River (Orleans, France) were carried
out according to a protocol approved by the Committee for
Animal Experiments for the Canton of Vaud, Switzerland
(license 2772). LS174T colorectal adenocarcinoma cells (Cell
Line Service GmbH, Eppelheim, Germany) were cultured in
DMEM culture medium (Gibco, Carlsbad, USA) supplemented
with 10% heat-inactivated fetal calf serum and 1% antibiotics
(Sigma-Aldrich, St. Luis, USA). Mice were injected subcutane-
ously in the hind le leg with 5  105 LS174T cells resuspended
in culture medium. When tumors reached a size of 5–6 mm in
diameter, i.e. on day 6, mice received 12.5 mg kg1 of either 1 or
2 in 10% DMSO in saline as 300 mL i.p. injection with or without
hyperthermia (30 minutes at 42 C, drug-heat interval of <15
minutes). Commercially available heating pads (Thermopad,
10200034 type 226, Solis AG – Switzerland, 30  40 cm heated
pad, with 100 watt output and 6 temperature settings) to locally
heat a subcutaneous tumor in the hind leg were used. To
minimize the stress due to hyperthermia treatment immobili-
zation anesthesia was carried out under 2.5% isourane and
kept under 1.5% of isourane for the duration of the experi-
ment with a humidied isouorane system (Rothhacher GmbH,
Bern, Switzerland). This treatment was repeated following theThis journal is © The Royal Society of Chemistry 2015q4d3 schedule, i.e. a total of 3 doses at 4 day intervals. Tumor
dimensions and body weight were measured daily. Tumor
volumes (mm3) were calculated using the following formula
volume ¼ width2  length  0.5. At the end of the experiment,
when the control tumor size reached 1000 mm3 the mice were
euthanized and the tumors resected and xed in formalin
solution for immunohistochemistry. Blood, part of tumors and
organs were snap-frozen for ruthenium distribution
measurements.
Immunohistochemistry
Tumor sections (5 mm) were blocked with 5% BSA in PBS and
incubated with primary antibodies against Ki-67 (mouse anti-
human Ki-67; 1 : 200, clone 1A4, Dako, Gostrup, Denmark).
This step was followed by the addition of alkaline phosphatase
conjugated polymer Mach 2 (Biocare Medical, Concord, USA)
and visualized by Fast Blue BB/Naphthol-AS-MX-Phosphate,
resulting in a blue/purple-colored precipitate. Hematoxylin and
eosin staining was routinely preformed. Briey, sections were
deparaﬃnized in xylene I, II and III, washed and stained in
hematoxylin (Harris Hematoxylin, Sigma) followed by eosin
staining. In the next step they were dehydrated by washing in
ethanol and mounted with DPX mountant and coverslip.
Sections were imaged using Olympus microscope IX81 con-
nected to Leica 200 scientic camera.
Drug distribution measurements
Tissues of interest were collected, weight and dried until their
weight remained constant. Samples were digested in concen-
trated nitric acid (1 mL) for 2 days. Samples were completed to a
total volume of 8 mL with water. Indium was added as an
internal standard at a concentration of 0.5 ppb. Determination
of the metal content was achieved using an Elan DRC II ICP-MS
instrument (Perkin-Elmer, Switzerland) equipped with a Mein-
hard nebulizer and a cyclonic spray chamber. The ICP-MS
instrument was tuned using a solution containing 1 ppb of the
following elements: Mg, In, Ce, Ba, Pb and U. External stan-
dards were prepared gravimetrically in an identical matrix to
the samples with single element standards obtained from CPI
International (Amsterdam, The Netherlands). Values were
normalized per mg of wet tissue.
Drug eﬃcacy and synergy calculation
Drug eﬃcacy (DE), or tumor regression, was calculated from the
tumor growth of the treated group (T) and the control group (C)
using the relation: DE ¼ 1  T/C. A synergy between the drug
and hyperthermia was calculated with the fractional product
method (for independent inhibitors).48 Limited to the nal
dose-point, the isobologram resulting from the Chou–Talalay
combination index method cannot be built since it needs two
points for each monotherapy. Nevertheless, the fractional
product gives a rst insight at the synergistic level between 1
and hyperthermia with the formula: f1,H ¼ f1  f1,H, where f1,H,
f1, and f1,H are fractions of the total activity unaﬀected by the
combination of 1 + hyperthermia, 1 and hyperthermia, respec-
tively. Using drug eﬃcacy (tumor reduction) values from theChem. Sci., 2015, 6, 2795–2801 | 2799
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View Article Onlinetumor growth curves: f1  fH ¼ (1  DE1) (1  DEH) ¼ 0.226.
Therefore, the combination 1 with hyperthermia was consid-
ered as synergistic if: DE1,H > 1  0.226 ¼ 0.774, which was the
case as DE1,H ¼ 0.787. In the same way, for a synergistic
eﬀect between 2 with hyperthermia the value must be higher
than: 1  (1  DE2)(1  DEH) ¼ 0.812, where DE2 ¼ 0.656 and
DEH ¼ 0.454, which was the case as DE2,H ¼ 0.899.
Toxicity evaluation
To monitor the toxicity during the treatment the mice were
observed daily in terms of relevant indexes such as body weight,
appearance, provoked and natural behavior change and food
and water intake.
Statistical analysis
Tumor growth values are given as median values  standard
error of themean. Statistical analysis was conducted using the R
soware (version 3.1.0).49 ANOVA tests were used to assess the
signicance of results and were accompanied by one-sided
pairwise t-test ad-hoc analysis. *p < 0.05, **p < 0.01, ***p <
0.001.
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